论文部分内容阅读
选取65例合并LOH的男性2型糖尿病男性,其中35例为实验组,30例为对照组。实验组给予口服十一酸睾酮(安特尔)20mg 3次/日,共6个月,对照组不予替代治疗。观察基线和治疗6个月后的AMS评分、血清总睾酮(TT)、空腹血糖(FPG)、空腹胰岛素(FINS)、HOMA-IR、糖化血红蛋白(HbA_(1C))、甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白(LDL-C)变化情况。结果实验组治疗后AMS量表评分明显下降,与对照组差异显著(P<0.05);实验组治疗后TT、FPG、FINS、HOMA-IR、HbA_(1C)、TG、TC、LDL-C均有明显改善,且两组比较差异显著(P<0.05)。实验组患者治疗过程中未发生明显不良反应。结论对合并LOH的男性2型糖尿病患者进行小剂量TRT安全有效。
Sixty-five male patients with type 2 diabetes mellitus with LOH were selected, of which 35 were experimental group and 30 were control group. The experimental group was given oral testosterone undecanoate (Atel) 20mg 3 times / day, a total of 6 months, the control group did not replace the treatment. AMS score, serum total testosterone (TT), fasting plasma glucose (FPG), fasting insulin (FINS), HOMA-IR, HbA 1c and triglyceride were observed at baseline and 6 months after treatment. , Cholesterol (TC), low density lipoprotein (LDL-C) changes. Results The scores of AMS in experimental group decreased significantly compared with that in control group (P <0.05). The levels of TT, FPG, FINS, HOMA-IR, HbA 1 C, TG, TC and LDL-C There was a significant improvement, and the difference between the two groups was significant (P <0.05). No significant adverse reactions occurred in the experimental group during the course of treatment. Conclusion Low dose TRT is safe and effective for type 2 diabetic patients with LOH.